Strong commercial momentum for BRINSUPRI and continued growth from ARIKAYCE prompted Insmed to raise its 2026 outlook and increase peak revenue expectations for its lead programmes.
Key Investor Takeaways – Insmed (NASDAQ:INSM) reported second-quarter revenue of $425.5 million, led by strong BRINSUPRI sales. – BRINSUPRI generated $309.2 million in quarterly revenue, increasing 49% from the first quarter and prompting higher 2026 revenue guidance. – The company raised its 2026 BRINSUPRI revenue outlook to $1.25 billion-$1.40 billion while maintaining ARIKAYCE guidance of $450 million-$470 million. – Insmed increased its combined peak revenue estimate for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion. – Multiple Phase 3 programmes and regulatory milestones remain on track across the company’s respiratory pipeline
Why INSM Stock Is in Focus Insmed (NASDAQ:INSM) reported total second-quarter 2026 revenue of $425.5 million, driven by continued commercial strength from BRINSUPRI, which generated $309.2 million in sales during the quarter. The product’s revenue increased 49% sequentially, reflecting continued adoption following its launch in the United States. ARIKAYCE contributed $116.3 million in quarterly revenue, representing 8% year-over-year growth, supported primarily by international markets.
Following the strong commercial performance, Insmed raised its 2026 BRINSUPRI revenue guidance to a range of $1.25 billion to $1.40 billion while reaffirming its ARIKAYCE revenue outlook of $450 million to $470 million. The company also increased its long-term outlook for its lead commercial and late-stage programmes, now projecting combined peak annual revenue of more than $14 billion, consisting of more than $7 billion for BRINSUPRI, more than $6 billion for TPIP and more than $1 billion for ARIKAYCE. Why This Matters for Investors The higher BRINSUPRI guidance suggests the launch is outperforming previous expectations and reinforces the product’s position as…